VENCLEXTA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Venclexta, and when can generic versions of Venclexta launch?
Venclexta is a drug marketed by Abbvie and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and fifty-nine patent family members in forty-three countries.
The generic ingredient in VENCLEXTA is venetoclax. One supplier is listed for this compound. Additional details are available on the venetoclax profile page.
DrugPatentWatch® Generic Entry Outlook for Venclexta
Venclexta was eligible for patent challenges on April 11, 2020.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 23, 2032. This may change due to patent challenges or generic licensing.
There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VENCLEXTA?
- What are the global sales for VENCLEXTA?
- What is Average Wholesale Price for VENCLEXTA?
Summary for VENCLEXTA
| International Patents: | 259 |
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 98 |
| Clinical Trials: | 189 |
| Patent Applications: | 1,167 |
| Drug Prices: | Drug price information for VENCLEXTA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VENCLEXTA |
| What excipients (inactive ingredients) are in VENCLEXTA? | VENCLEXTA excipients list |
| DailyMed Link: | VENCLEXTA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VENCLEXTA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VENCLEXTA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Antonio M Jimenez Jimenez | Phase 1 |
| Montefiore Medical Center | Phase 1 |
| Flamingo Therapeutics NV | Phase 1 |
Pharmacology for VENCLEXTA
| Drug Class | BCL-2 Inhibitor |
| Mechanism of Action | P-Glycoprotein Inhibitors |
| Physiological Effect | Increased Cellular Death |
Paragraph IV (Patent) Challenges for VENCLEXTA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VENCLEXTA | Tablets | venetoclax | 10 mg, 50 mg and 100 mg | 208573 | 2 | 2020-04-13 |
US Patents and Regulatory Information for VENCLEXTA
VENCLEXTA is protected by fourteen US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VENCLEXTA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VENCLEXTA
Salts and crystalline forms of an apoptosis-inducing agent
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK
Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
Melt-extruded solid dispersions containing an apoptosis-inducing agent
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULTS WITH RELAPSED, REFRACTORY OR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA INCLUDING A DOSE RAMP-UP AND IN COMBINATION WITH OBINUTUZUMAB IN MULTIPLE 28-DAY DOSING CYCLES FOLLOWED BY ADMINISTRATION IN ABSENCE OF OBINUTUZUMAB
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF AML BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE TO ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES PER A DOSE RAMP-UP INCLUDING AN INITIAL 100 MG OR A FINAL 400 MG PER DAY DOSE
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Salts and crystalline forms of an apoptosis-inducing agent
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER
FDA Regulatory Exclusivity protecting VENCLEXTA
INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
Exclusivity Expiration: ⤷ Sign Up
INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-002 | Apr 11, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for VENCLEXTA
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| AbbVie Deutschland GmbH Co. KG | Venclyxto | venetoclax | EMEA/H/C/004106 Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.Venclyxto monotherapy is indicated for the treatment of CLL:- in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor, or- in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. |
Authorised | no | no | no | 2016-12-04 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for VENCLEXTA
When does loss-of-exclusivity occur for VENCLEXTA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 3656
Patent: DISPERSIONES SOLIDAS EXTRUIDAS POR FUSION QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS, PROCESO PARA PREPARAR, METODO DE TRATAMIENTO
Estimated Expiration: ⤷ Sign Up
Patent: 2475
Patent: DISPERSIONES SÓLIDAS EXTRUIDAS POR FUSIÓN QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 11361704
Patent: Melt-extruded solid dispersions containing an apoptosis-inducing agent
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2013010524
Patent: dispersões sólidas extrusadas por fusão contendo um agente indutor de apoptose
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 13985
Patent: DISPERSIONS SOLIDES EXTRUDEES EN FUSION CONTENANT UN AGENT INDUISANT L'APOPTOSE (MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 13001120
Patent: Una dispersion solida que comprende un agente inductor de apoptosis de formula definida dispersado en una matriz solida que comprende a) al menos un vehiculo polimerico soluble en agua y b) al menos un surfactante; proceso de preparacion; forma de dosificacion oral, util para tratar una enfermedad neoplasica, inmune o autoinmune.
Estimated Expiration: ⤷ Sign Up
China
Patent: 3282025
Patent: Melt-extruded solid dispersions containing an apoptosis-nducing agent
Estimated Expiration: ⤷ Sign Up
Patent: 8175749
Patent: 含有细胞凋亡诱导剂的熔体挤出的固体分散体 (Melt-extruded solid dispersions containing apoptosis-inducing agent)
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 81472
Patent: Dispersiones sólidas extruidas por fusión que contienen un agente inductor de apoptosis
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 130224
Patent: DISPERSIONES SÓLIDAS EXTRUIDAS POR FUSIÓN QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS
Estimated Expiration: ⤷ Sign Up
Patent: 180289
Patent: DISPERSIONES SÓLIDAS EXTRUIDAS POR FUSIÓN QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS (Divisional 2013-0224)
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0171884
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 19993
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 13769
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 013000092
Patent: DISPERSIONES SOLIDAS EXTRUIDAS POR FUSION QUE CONTIENEN UN AGENTE INDUCTOR DE ADOPTOSIS
Estimated Expiration: ⤷ Sign Up
Patent: 017000003
Patent: DISPERSIONES SÓLIDAS EXTRUIDAS POR FUSIÓN QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 13012647
Patent: DISPERSIONES SÓLIDAS EXTRUIDAS POR FUSIÓN QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS
Estimated Expiration: ⤷ Sign Up
Patent: 22086925
Patent: DISPERSIONES SÓLIDAS EXTRUIDAS POR FUSIÓN QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 13769
Patent: DISPERSIONS SOLIDES EXTRUDÉES EN FUSION CONTENANT UN AGENT INDUISANT L'APOPTOSE (MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT)
Estimated Expiration: ⤷ Sign Up
Patent: 19308
Patent: DISPERSIONS SOLIDES EXTRUDÉES PAR FUSION CONTENANT UN AGENT INDUISANT L'APOPTOSE (MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT)
Estimated Expiration: ⤷ Sign Up
Patent: 18731
Patent: DISPERSIONS SOLIDES EXTRUDÉES À L'ÉTAT FONDU CONTENANT UN AGENT INDUISANT L'APOPTOSE (MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT)
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 1300102
Patent: DISPERSIONES SOLIDAS EXTRUIDAS POR FUSION QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 43761
Patent: 含有細胞凋亡誘導劑的熔體擠出的固體分散體 (MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 35169
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 6215
Patent: דיספרסיות מוצקות מהתכה ושיחול המכילות חומר המשרה מוות מתוכנן של תאים (Melt-extruded solid dispersions containing an apoptosis-inducing agent)
Estimated Expiration: ⤷ Sign Up
Patent: 1877
Patent: דיספרסיות מוצקות מהתכה ושיחול המכילות חומר המשרה מוות מתוכנן של תאים (Melt-extruded solid dispersions containing an apoptosis-inducing agent)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 02187
Estimated Expiration: ⤷ Sign Up
Patent: 53638
Estimated Expiration: ⤷ Sign Up
Patent: 13544804
Estimated Expiration: ⤷ Sign Up
Patent: 16147878
Patent: アポトーシス誘発剤を含む溶融押出固体分散体 (MELT-EXTRUDED SOLID DISPERSION CONTAINING APOPTOSIS-INDUCING AGENT)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 13769
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 9224
Patent: MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 5603
Patent: DISPERSIONES SÓLIDAS EXTRUIDAS POR FUSION QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS. (MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT.)
Estimated Expiration: ⤷ Sign Up
Patent: 2113
Patent: DISPERSIONES SOLIDAS EXTRUIDAS POR FUSION QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS. (MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT.)
Estimated Expiration: ⤷ Sign Up
Patent: 13004843
Patent: DISPERSIONES EXTRUIDAS POR FUSION QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS. (MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT.)
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 942
Patent: KRUTA DISPERZIJA DOBIVENA EKSTRUZIJOM U RASTALJENOM STANJU KOJA SADRŽAVA AGENS ZA INDUCIRANJE APOPTOZE (MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 8907
Patent: Melt-extruded solid dispersions containing an apoptosis-inducing agent
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 13769
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 140381
Patent: DISPERSIONES SOLIDAS EXTRUIDAS POR FUSION QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS
Estimated Expiration: ⤷ Sign Up
Patent: 171242
Patent: DISPERSIONES SOLIDAS EXTRUIDAS POR FUSION QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 13769
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 13769
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 77859
Patent: ПОЛУЧЕННЫЕ ЭКСТРУЗИЕЙ РАСПЛАВА ТВЕРДЫЕ ДИСПЕРСИИ, СОДЕРЖАЩИЕ ИНДУЦИРУЮЩЕЕ АПОПТОЗ СРЕДСТВО (SOLID DISPERSIONS PRODUCED BY MELT EXTRUSION AND CONTAINING APOPTOSIS-INDUCING AGENT)
Estimated Expiration: ⤷ Sign Up
Patent: 33353
Patent: ПОЛУЧЕННЫЕ ЭКСТРУЗИЕЙ РАСПЛАВА ТВЕРДЫЕ ДИСПЕРСИИ, СОДЕРЖАЩИЕ ИНДУЦИРУЮЩЕЕ АПОПТОЗ СРЕДСТВО (SOLID DISPERSIONS PRODUCED BY MELT EXTRUSION AND CONTAINING APOPTOSIS-INDUCING AGENT)
Estimated Expiration: ⤷ Sign Up
Patent: 13124823
Patent: ПОЛУЧЕННЫЕ ЭКСТРУЗИЕЙ ТВЕРДЫЕ ДИСПЕРСИИ, СОДЕРЖАЩИЕ ИНДУЦИРУЮЩЕЕ АПАПТОЗ СРЕДСТВО
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 718
Patent: RASTOPOM-EKSTRUDIRANE ČVRSTE DISPERZIJE KOJE SADRŽE AGENS KOJI INDUKUJE APOPTOZU (MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 9477
Patent: MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
Estimated Expiration: ⤷ Sign Up
Patent: 14015077
Patent: MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 13769
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1302669
Patent: MELT-EXTRUDED SOLID DISPESIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
Estimated Expiration: ⤷ Sign Up
Patent: 1401440
Patent: PROCESS FOR PREPARING A SOLID DISPERSION CONTAINING AN APOPTOSIS-INDUCING AGENT
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1836820
Estimated Expiration: ⤷ Sign Up
Patent: 1957137
Estimated Expiration: ⤷ Sign Up
Patent: 140052921
Patent: MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
Estimated Expiration: ⤷ Sign Up
Patent: 180024025
Patent: 아폽토시스―유도제를 포함하는 용융―압출된 고체 분산체 (MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 47583
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 35699
Estimated Expiration: ⤷ Sign Up
Patent: 48261
Estimated Expiration: ⤷ Sign Up
Patent: 1242946
Patent: Melt-extruded solid dispersions containing an apoptosis-inducing agent
Estimated Expiration: ⤷ Sign Up
Patent: 1636324
Patent: Melt-extruded solid dispersions containing an apoptosis-inducing agent
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 3500
Patent: ОДЕРЖАНІ ЕКСТРУЗІЄЮ РОЗПЛАВУ ТВЕРДІ ДИСПЕРСІЇ, ЩО МІСТЯТЬ ІНДУКУЮЧИЙ АПОПТОЗ ЗАСІБ
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 692
Patent: DISPERSIONES SÓLIDAS EXTRUIDAS POR FUSIÓN QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS
Estimated Expiration: ⤷ Sign Up
Patent: 326
Patent: DISPERSIONES SÓLIDAS EXTRUIDAS POR FUSIÓN QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS
Estimated Expiration: ⤷ Sign Up
Patent: 192
Patent: DISPERSIÓN SÓLIDA, PROCESO PARA PREPARARLA Y FORMA DE DOSIFICACIÓN FARMACÉUTICA SUMINISTRABLE POR VÍA ORAL QUE LA COMPRENDE
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VENCLEXTA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20180049164 | 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제 (- Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases) | ⤷ Sign Up |
| Brazil | 112013010524 | dispersões sólidas extrusadas por fusão contendo um agente indutor de apoptose | ⤷ Sign Up |
| Mexico | 2012013708 | AGENTES DE INDUCCION DE APOPTOSIS PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES INMUNES Y AUTOINMUNES. (APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES.) | ⤷ Sign Up |
| Cyprus | 2017019 | ⤷ Sign Up | |
| Finland | 2435432 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VENCLEXTA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2435432 | 2017/023 | Ireland | ⤷ Sign Up | PRODUCT NAME: VENETOCLAX (VENCLYXTO); REGISTRATION NO/DATE: EU/1/16/1138 20161205 |
| 2435432 | 693 | Finland | ⤷ Sign Up | |
| 2435432 | SPC/GB17/032 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: VENETOCLAX; REGISTERED: UK EU/1/16/1138 (NI) 20161207; UK PLGB 41042/0035 20161207; UK PLGB 41042/0036 20161207; UK PLGB 41042/0037 20161207 |
| 2435432 | CR 2017 00021 | Denmark | ⤷ Sign Up | PRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138/001-007 20161207 |
| 2435432 | 386 50008-2017 | Slovakia | ⤷ Sign Up | PRODUCT NAME: VENETOKLAX; REGISTRATION NO/DATE: EU/1/16/1138 20161207 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
